Lise Tarnow

List of Publications by Year
in descending order

243 papers	13,810 citations	14655 66 h-index	27406 106 g-index
246 all docs	246 docs citations	246 times ranked	14119 citing authors

#	Article	IF	Citations
1	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	3.8	434
2	Effect of liraglutide, a glucagonâ€like peptideâ€1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (<scp>LIVE</scp>)â€”a multicentre, doubleâ€blind, randomised, placeboâ€controlled trial. European Journal of Heart Failure, 2017, 19, 69-77.	7.1	343
3	Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ: British Medical Journal, 2004, 328, 1105.	2.3	337
4	Decreasing Incidence of Severe Diabetic Microangiopathy in Type 1 Diabetes. Diabetes Care, 2003, 26, 1258-1264.	8.6	325
5	Progression of diabetic nephropathy. Kidney International, 2001, 59, 702-709.	5.2	283
6	Progression of nephropathy in type 2 diabetic patients. Kidney International, 2004, 66, 1596-1605.	5.2	270
7	Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1283-1290.	6.1	267
8	Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney International, 2000, 57, 601-606.	5.2	250
9	New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes. PLoS Genetics, 2012, 8, e1002921.	3.5	216
10	Aldosterone escape during blockade of the renin?angiotensin?aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia, 2004, 47, 1936-1939.	6.3	214
11	Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications. Diabetologia, 2005, 48, 1911-1918.	6.3	210
12	Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care, 2011, 34, 442-447.	8.6	202
13	Beneficial impact of spironolactone in diabetic nephropathy. Kidney International, 2005, 68, 2829-2836.	5.2	201
14	Serum Uric Acid as a Predictor for Development of Diabetic Nephropathy in Type 1 Diabetes. Diabetes, 2009, 58, 1668-1671.	0.6	194
15	Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2006, 70, 536-542.	5.2	189
16	Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrology Dialysis Transplantation, 2004, 19, 2784-2788.	0.7	188
17	Lack of Relationship Between an Insertion/Deletion Polymorphism in the Angiotensin Iâ€“Converting Enzyme Gene and Diabetic Nephropathy and Proliferative Retinopathy in IDDM Patients. Diabetes, 1995, 44, 489-494.	0.6	184
18	Elevated Plasma Asymmetric Dimethylarginine as a Marker of Cardiovascular Morbidity in Early Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2004, 27, 765-769.	8.6	180

#	Article	IF	Citations
19	Prevalence of Arterial Hypertension in Diabetic Patients Before and After the JNC-V. Diabetes Care, 1994, 17, 1247-1251.	8.6	162
20	Association Between Mannose-Binding Lectin and Vascular Complications in Type 1 Diabetes. Diabetes, 2004, 53, 1570-1576.	0.6	161
21	Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ: British Medical Journal, 1996, 313, 591-594.	2.3	158
22	Cardiac Autonomic Neuropathy Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 334-339.	8.6	156
23	Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries.. Diabetes, 1999, 48, 2446-2453.	0.6	143
24	Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. European Journal of Endocrinology, 2006, 154, 75-81.	3.7	132
25	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 221-232.	11.4	127
26	Vitamin D Levels and Mortality in Type 2 Diabetes. Diabetes Care, 2010, 33, 2238-2243.	8.6	126
27	Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney International, 2008, 74, 649-654.	5.2	124
28	Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney International, 2008, 73, 1419-1425.	5.2	121
29	Plasma Concentration of Asymmetric Dimethylarginine (ADMA) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2008, 31, 747-752.	8.6	121
30	Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus. Journal of Hypertension, 2013, 31, 2094-2102.	0.5	120
31	Exome sequencing-driven discovery of coding polymorphisms associated with common metabolic phenotypes. Diabetologia, 2013, 56, 298-310.	6.3	119
32	YKL-40, a Marker of Inflammation and Endothelial Dysfunction, Is Elevated in Patients With Type 1 Diabetes and Increases With Levels of Albuminuria. Diabetes Care, 2009, 32, 323-328.	8.6	117
33	Mannose-Binding Lectin as a Predictor of Microalbuminuria in Type 1 Diabetes. Diabetes, 2005, 54, 1523-1527.	0.6	111
34	Subclinical Coronary and Aortic Atherosclerosis Detected by Magnetic Resonance Imaging in Type 1 Diabetes With and Without Diabetic Nephropathy. Circulation, 2007, 115, 228-235.	1.6	111
35	Neutrophil Gelatinaseâ€Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a crossâ€sectional study and the effects of lisinopril. Diabetic Medicine, 2010, 27, 1144-1150.	2.3	111
36	Higher Plasma Soluble Receptor for Advanced Glycation End Products (sRAGE) Levels Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes, 2010, 59, 2027-2032.	0.6	109

#	Article	IF	Citations
37	Markers of Endothelial Dysfunction and Inflammation in Type 1 Diabetic Patients With or Without Diabetic Nephropathy Followed for 10 Years. Diabetes Care, 2008, 31, 1170-1176.	8.6	106
38	Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney International, 2000, 57, S56-S61.	5.2	101
39	Plasma Connective Tissue Growth Factor Is an Independent Predictor of End-Stage Renal Disease and Mortality in Type 1 Diabetic Nephropathy. Diabetes Care, 2008, 31, 1177-1182.	8.6	99
40	Plasma Growth Differentiation Factor-15 Independently Predicts All-Cause and Cardiovascular Mortality As Well As Deterioration of Kidney Function in Type 1 Diabetic Patients With Nephropathy. Diabetes Care, 2010, 33, 1567-1572.	8.6	98
41	Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia, 2006, 49, 2256-2262.	6.3	96
42	LeucoPatch system for the management of hard-to-heal diabetic foot ulcers in the UK, Denmark, and Sweden: an observer-masked, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 870-878.	11.4	95
43	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney International, 1998, 53, 1002-1006.	5.2	91
44	Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively11See Editorial by Steffes, p. 378. Kidney International, 2001, 60, 277-283.	5.2	89
45	Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy. Diabetologia, 1995, 38, 798-803.	6.3	87
46	Increased levels of mannan-binding lectin in type 1 diabetic patients with incipient and overt nephropathy. Diabetologia, 2005, 48, 198-202.	6.3	85
47	Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 631-641.	3.7	84
48	Genetic Variation in the Renin-Angiotensin System and Progression of Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 2843-2850.	6.1	83
49	Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. PLoS ONE, 2008, 3, e3363.	2.5	83
50	Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial. Lancet Diabetes and Endocrinology,the, 2014, 2, 553-561.	11.4	83
51	Endothelial dysfunction and low-grade inflammation and the progression of retinopathy in TypeÂ2 diabetes. Diabetic Medicine, 2007, 24, 969-976.	2.3	81
52	A Single Nucleotide Polymorphism within the Acetyl-Coenzyme A Carboxylase Beta Gene Is Associated with Proteinuria in Patients with Type 2 Diabetes. PLoS Genetics, 2010, 6, e1000842.	3.5	81
53	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney International, 1999, 56, S101-S105.	5.2	80
54	Mannose-Binding Lectin and Mortality in Type 2 Diabetes. Archives of Internal Medicine, 2006, 166, 2007.	3.8	79

#	Article	IF	Citations
55	Low Birth Weight: A Risk Factor for Development of Diabetic Nephropathy?. Diabetes, 1995, 44, 1405-1407.	0.6	77
56	Irbesartan Treatment Reduces Biomarkers of Inflammatory Activity in Patients With Type 2 Diabetes and Microalbuminuria: An IRMA 2 Substudy. Diabetes, 2006, 55, 3550-3555.	0.6	77
57	Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes. Diabetes Care, 2019, 42, 1512-1520.	8.6	77
58	Telomere length predicts all-cause mortality in patients with type 1 diabetes. Diabetologia, 2010, 53, 45-48.	6.3	76
59	A phase 2a, randomized, doubleâ€blind 28â€day study of TZPâ€102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology and Motility, 2013, 25, e140-50.	3.0	76
60	Predisposition to essential hypertension and development of diabetic nephropathy in IDDM patients. Diabetes, 1998, 47, 439-444.	0.6	74
61	Analysis of 14 Candidate Genes for Diabetic Nephropathy on Chromosome 3q in European Populations. Diabetes, 2006, 55, 3166-3174.	0.6	74
62	Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 731-738.	1.2	74
63	A Novel Algorithm for Prediction and Detection of Hypoglycemia Based on Continuous Glucose Monitoring and Heart Rate Variability in Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2014, 8, 731-737.	2.2	73
64	Elevated Levels of High-Molecular-Weight Adiponectin in Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3186-3191.	3.6	71
65	Improved prognosis in type 1 diabetic patients with nephropathy: A prospective follow-up study. Kidney International, 2005, 68, 1250-1257.	5.2	70
66	Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetologia, 2008, 51, 2100-2107.	6.3	70
67	Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients. Diabetes, 1995, 44, 489-494.	0.6	70
68	Genetic polymorphisms of the reninâ€“angiotensin system and complications of insulinâ€dependent diabetes mellitus. Nephrology Dialysis Transplantation, 2000, 15, 1000-1007.	0.7	69
69	Meta analysis. Diabetic nephropathy and the insertion/deletion polymorphism of the angiotensin-converting enzyme gene. Nephrology Dialysis Transplantation, 1998, 13, 1125-1130.	0.7	68
70	Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 1537-1543.	6.1	66
71	Association between Angiotensin-Converting Enzyme Gene Polymorphisms and Diabetic Nephropathy: Case-Control, Haplotype, and Family-Based Study in Three European Populations. Journal of the American Society of Nephrology: JASN, 2007, 18, 1284-1291.	6.1	64
72	Tubular and Glomerular Injury in Diabetes and the Impact of ACE Inhibition. Diabetes Care, 2009, 32, 1684-1688.	8.6	64

#	Article	IF	Citations
73	Angiotensinogen Gene Polymorphisms in IDDM Patients With Diabetic Nephropathy. Diabetes, 1996, 45, 367-369.	0.6	63
74	Remission of Nephrotic-Range Albuminuria in Type 1 Diabetic Patients. Diabetes Care, 2001, 24, 1972-1977.	8.6	63
75	Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study. Diabetes, 2017, 66, 2278-2283.	0.6	63
76	Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes. Diabetes, 2011, 60, 3073-3080.	0.6	62
77	Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy. Diabetes Care, 2003, 26, 1501-1506.	8.6	60
78	Plasma renin and prorenin and renin gene variation in patients with insulin-dependent diabetes mellitus and nephropathy. Nephrology Dialysis Transplantation, 1999, 14, 1904-1911.	0.7	58
79	Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia, 2005, 48, 149-155.	6.3	58
80	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology, 2004, 24, 147-157.	1.6	57
81	Short stature and diabetic nephropathy. BMJ: British Medical Journal, 1995, 310, 296-297.	2.3	55
82	Soccer Training Improves Cardiac Function in Men with Type 2 Diabetes. Medicine and Science in Sports and Exercise, 2013, 45, 2223-2233.	0.4	54
83	Plasminogen activator inhibitorâ€1 and apolipoprotein E gene polymorphisms and diabetic angiopathy. Nephrology Dialysis Transplantation, 2000, 15, 625-630.	0.7	53
84	Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2000, 23, 30-33.	8.6	53
85	Osteoprotegerin and Mortality in Type 2 Diabetic Patients. Diabetes Care, 2010, 33, 2561-2566.	8.6	53
86	Smoking and Progression of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2003, 26, 911-916.	8.6	52
87	QT interval prolongation during spontaneous episodes of hypoglycaemia in type 1 diabetes: the impact of heart rate correction. Diabetologia, 2010, 53, 2036-2041.	6.3	52
88	Urinary Connective Tissue Growth Factor Excretion Correlates With Clinical Markers of Renal Disease in a Large Population of Type 1 Diabetic Patients With Diabetic Nephropathy. Diabetes Care, 2006, 29, 83-88.	8.6	52
89	Insulin analogues and severe hypoglycaemia in type 1 diabetes. Diabetes Research and Clinical Practice, 2012, 96, 17-23.	2.8	51
90	A combined abnormality in heart rate variation and QT corrected interval is a strong predictor of cardiovascular death in type 1 diabetes. Scandinavian Journal of Clinical and Laboratory Investigation, 2008, 68, 654-659.	1.2	50

#	Article	IF	Citations
91	Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes. Diabetologia, 2014, 57, 1143-1153.	6.3	50
92	Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovascular Diabetology, 2017, 16, 55.	6.8	47
93	The V16A polymorphism in SOD2 is associated with increased risk of diabetic nephropathy and cardiovascular disease in type 1 diabetes. Diabetologia, 2009, 52, 2590-2593.	6.3	45
94	Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatmentâ€“resistant hypertension. Journal of the American Society of Hypertension, 2014, 8, 872-881.	2.3	45
95	The methylglyoxal-derived AGE tetrahydropyrimidine is increased in plasma of individuals with type 1 diabetes mellitus and in atherosclerotic lesions and is associated with sVCAM-1. Diabetologia, 2013, 56, 1845-1855.	6.3	44
96	SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes. Diabetologia, 2015, 58, 543-548.	6.3	43
97	PGC-1Î± Gly482Ser Polymorphism Associates With Hypertension Among Danish Whites. Hypertension, 2005, 45, 565-570.	2.7	42
98	Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 966-977.	4.4	42
99	Nocturnal Continuous Glucose Monitoring: Accuracy and Reliability of Hypoglycemia Detection in Patients with Type 1 Diabetes at High Risk of Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2013, 15, 371-377.	4.4	42
100	Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney International, 2005, 67, 2325-2329.	5.2	41
101	Plasma Î±-Defensin Is Associated with Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1470-1475.	3.6	41
102	Model Study of the Pressure Build-Up during Subcutaneous Injection. PLoS ONE, 2014, 9, e104054.	2.5	41
103	Glucose-Dependent Insulinotropic Polypeptide Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB. Diabetes, 2016, 65, 239-254.	0.6	41
104	Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. Kidney International, 2004, 66, 1180-1186.	5.2	40
105	Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, Obesity and Metabolism, 2007, 9, 394-407.	4.4	40
106	G/T Substitution in Intron 1 of the UNC13B Gene Is Associated With Increased Risk of Nephropathy in Patients With Type 1 Diabetes. Diabetes, 2008, 57, 2843-2850.	0.6	39
107	The endothelial nitric oxide synthase gene and risk of diabetic nephropathy and development of cardiovascular disease in type 1 diabetes. Molecular Genetics and Metabolism, 2009, 97, 80-84.	1.1	37
108	Arterial stiffness and endothelial dysfunction independently and synergistically predict cardiovascular and renal outcome in patients with type 1 diabetes. Diabetic Medicine, 2012, 29, 990-994.	2.3	37

#	Article	IF	Citations
109	Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci. Immunologic Research, 2016, 64, 55-63.	2.9	37
110	Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. Nephrology Dialysis Transplantation, 1996, 11, 1019-1023.	0.7	36
111	Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy. Proteome Science, 2010, 8, 4.	1.7	36
112	Use of an autologous leucocyte and platelet-rich fibrin patch on hard-to-heal DFUs: a pilot study. Journal of Wound Care, 2015, 24, 172-178.	1.2	36
113	Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial. Diabetic Medicine, 2015, 32, 374-381.	2.3	35
114	Prevalence of left ventricular hypertrophy in Type I diabetic patients with diabetic nephropathy. Diabetologia, 1999, 42, 76-80.	6.3	33
115	Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study. Cardiovascular Diabetology, 2010, 9, 40.	6.8	33
116	Prevalence of gastroparesis-related symptoms in an unselected cohort of patients with Type 1 diabetes. Journal of Diabetes and Its Complications, 2012, 26, 89-93.	2.3	33
117	Hypoglycemia-Associated Changes in the Electroencephalogram in Patients With Type 1 Diabetes and Normal Hypoglycemia Awareness or Unawareness. Diabetes, 2015, 64, 1760-1769.	0.6	33
118	Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ: British Medical Journal, 2009, 339, b4324-b4324.	2.3	32
119	Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial. Diabetologia, 2009, 52, 46-49.	6.3	32
120	At least one in three people with TypeÂ2 diabetes mellitus referred to a diabetes centre has symptomatic obstructive sleep apnoea. Diabetic Medicine, 2014, 31, 1460-1467.	2.3	32
121	IGFBP-4 Fragments as Markers of Cardiovascular Mortality in Type 1 Diabetes Patients With and Without Nephropathy. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3032-3040.	3.6	32
122	Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype?. Kidney International, 2002, 62, 192-198.	5.2	30
123	Total plasma homocysteine is associated with hypertension in Type I diabetic patients. Diabetologia, 2002, 45, 1315-1324.	6.3	30
124	European rational approach for the genetics of diabetic complications EURAGEDIC: patient populations and strategy. Nephrology Dialysis Transplantation, 2007, 23, 161-168.	0.7	30
125	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. Platelets, 2010, 21, 525-532.	2.3	30
126	Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitusâ€"the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008376.	1.9	30

#	Article	IF	Citations
127	Lack of synergism between long-term poor glycaemic control and three gene polymorphisms of the renin angiotensin system on risk of developing diabetic nephropathy in Type I diabetic patients. Diabetologia, 2000, 43, 794-799.	6.3	29
128	Higher plasma high-mobility group box 1 levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12Âyear follow-up study. Diabetologia, 2012, 55, 2489-2493.	6.3	29
129	Real-Time Hypoglycemia Detection from Continuous Glucose Monitoring Data of Subjects with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2013, 15, 538-543.	4.4	29
130	Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. Platelets, 2009, 20, 513-519.	2.3	28
131	Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients. Clinical Proteomics, 2010, 6, 105-114.	2.1	28
132	Combining Information of Autonomic Modulation and CGM Measurements Enables Prediction and Improves Detection of Spontaneous Hypoglycemic Events. Journal of Diabetes Science and Technology, 2015, 9, 132-137.	2.2	28
133	Progression of diabetic nephropathy: Role of plasma homocysteine and plasminogen activator inhibitor-1. American Journal of Kidney Diseases, 2001, 38, 1376-1380.	1.9	27
134	Screening for Diabetic Cardiac Autonomic Neuropathy Using a New Handheld Device. Journal of Diabetes Science and Technology, 2012, 6, 965-972.	2.2	27
135	Obstructive sleep apnoea is frequent in patients with type 1 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 156-161.	2.3	27
136	Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. Cardiovascular Diabetology, 2017, 16, 139.	6.8	27
137	Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 35-46.	3.7	26
138	Study rationale and design of the CIMT trial: The Copenhagen Insulin and Metformin Therapy Trial. Diabetes, Obesity and Metabolism, 2009, 11, 315-322.	4.4	26
139	Glycemic Variability Is Associated With Reduced Cardiac Autonomic Modulation in Women With Type 2 Diabetes. Diabetes Care, 2015, 38, 682-688.	8.6	25
140	Effect of insulin analogues on frequency of non-severe hypoglycaemia in patients with typeÂ1 diabetes prone to severe hypoglycaemia: The HypoAna trial. Diabetes and Metabolism, 2016, 42, 249-255.	2.9	25
141	Association of aldose reductase gene Z+2 polymorphism with reduced susceptibility to diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabetic Medicine, 2004, 21, 867-873.	2.3	24
142	Long-term prevention of diabetic nephropathy: an audit. Diabetologia, 2008, 51, 956-961.	6.3	24
143	The PPARÎ³2 Pro12Ala variant predicts ESRD and mortality in patients with type 1 diabetes and diabetic nephropathy. Molecular Genetics and Metabolism, 2008, 94, 347-351.	1.1	24
144	Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrology Dialysis Transplantation, 2011, 26, 3242-3249.	0.7	24

#	Article	IF	Citations
145	Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy. Kidney International, 2017, 92, 1242-1248.	5.2	24
146	The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporosis International, 2018, 29, 2517-2526.	3.1	24
147	Remission and regression of diabetic nephropathy. Current Hypertension Reports, 2004, 6, 377-382.	3.5	23
148	The prevalence of coeliac disease in adult Danish patients with type 1 diabetes with and without nephropathy. Diabetologia, 2005, 48, 1416-1417.	6.3	23
149	Carotid intima-media thickness is reduced 12months after gastric bypass surgery in obese patients with type 2 diabetes or impaired glucose tolerance. Journal of Diabetes and Its Complications, 2014, 28, 517-522.	2.3	23
150	Hypoglycaemia and QT interval prolongation in type 1 diabetes â€“ bridging the gap between clamp studies and spontaneous episodes. Journal of Diabetes and Its Complications, 2014, 28, 723-728.	2.3	23
151	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids, 2012, 42, 1627-1639.	2.7	22
152	A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	g.9	22
153	Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study. Diabetes Care, 2015, 38, 1898-1903.	8.6	22
154	Influence of Erythropoietin on Cognitive Performance during Experimental Hypoglycemia in Patients with Type 1 Diabetes Mellitus: A Randomized Cross-Over Trial. PLoS ONE, 2013, 8, e59672.	2.5	22
155	Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy. Nephrology Dialysis Transplantation, 2003, 18, 293-297.	0.7	21
156	SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes. Diabetologia, 2012, 55, 2386-2393.	6.3	21
157	Professional Continuous Glucose Monitoring in Subjects with Type 1 Diabetes: Retrospective Hypoglycemia Detection. Journal of Diabetes Science and Technology, 2013, 7, 135-143.	2.2	21
158	Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy?. Kidney International, 2006, 69, 1293-1295.	5.2	20
159	Finding diabetic nephropathy biomarkers in the plasma peptidome by highâ€throughput magnetic bead processing and MALDIâ€TOFâ€MS analysis. Proteomics - Clinical Applications, 2010, 4, 697-705.	1.6	20
160	Left ventricular hypertrophy in normoalbuminuric type 2 diabetic patients not taking antihypertensive treatment. QJM - Monthly Journal of the Association of Physicians, 2005, 98, 879-884.	0.5	19
161	A polymorphism in the gene encoding carnosinase (CNDP1) as a predictor of mortality and progression from nephropathy to end-stage renal disease in type 1 diabetes mellitus. Diabetologia, 2010, 53, 2562-2568.	6.3	19
162	Cardiovascular Autonomic Neuropathy Is Associated With Macrovascular Risk Factors in Type 2 Diabetes. Journal of Diabetes Science and Technology, 2014, 8, 874-880.	2.2	19

#	Article	IF	Citations
163	Novel genetic susceptibility loci for diabetic end-stage renal disease identified through robust naive Bayes classification. Diabetologia, 2014, 57, 1611-1622.	6.3	19
164	A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design. BMC Endocrine Disorders, 2012, 12, 10.	2.2	18
165	Accuracy Evaluation of a New Real-Time Continuous Glucose Monitoring Algorithm in Hypoglycemia. Diabetes Technology and Therapeutics, 2014, 16, 667-678.	4.4	18
166	Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Journal of Diabetes Research, 2015, 2015, 1-11.	2.3	18
167	Prediction of In-Hospital Pressure Ulcer Development. Advances in Wound Care, 2019, 8, 1-6.	5.1	18
168	Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study. Journal of Nuclear Cardiology, 2019, 26, 585-597.	2.1	18
169	Evaluation of an Algorithm for Retrospective Hypoglycemia Detection Using Professional Continuous Glucose Monitoring Data. Journal of Diabetes Science and Technology, 2014, 8, 117-122.	2.2	17
170	Effect of Insulin Analogs on Frequency of Nonâ€“Severe Hypoglycemia in Patients with Type 1 Diabetes Prone to Severe Hypoglycemia: Much Higher Rates Detected by Continuous Glucose Monitoring than by Self-Monitoring of Blood Glucoseâ€”The HypoAna Trial. Diabetes Technology and Therapeutics, 2018, 20, 247-256.	4.4	17
171	Birth weight - a risk factor for progression in diabetic nephropathy?. Journal of Internal Medicine, 2003, 253, 343-350.	6.0	16
172	Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes. Journal of Diabetes and Its Complications, 2013, 27, 604-608.	2.3	16
173	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 734-738.	4.4	16
174	The impact of the glucagonâ€like peptideâ€1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2141-2150.	4.4	16
175	Impact of polymorphisms in the genes encoding xylosyltransferase I and a homologue in type 1 diabetic patients with and without nephropathy. Kidney International, 2005, 68, 1483-1490.	5.2	15
176	Elevated Placental Growth Factor (PlGF) Predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients with Diabetic Nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 73-79.	1.2	15
177	Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrology Dialysis Transplantation, 2007, 22, 3235-3239.	0.7	15
178	Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. European Journal of Endocrinology, 2011, 164, 371-379.	3.7	15
179	The LeucoPatchÂ® system in the management of hard-to-heal diabetic foot ulcers: study protocol for a randomised controlled trial. Trials, 2017, 18, 469.	1.6	15
180	CYP2C9 variant modifies blood pressure-lowering response to losartan in Type 1 diabetic patients with nephropathy. Diabetic Medicine, 2007, 24, 323-325.	2.3	14

#	Article	IF	Citations
181	Identification of a xylosyltransferase II gene haplotype marker for diabetic nephropathy in type 1 diabetes. Clinica Chimica Acta, 2008, 398, 90-94.	1.1	14
182	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, 73-77.	0.9	14
183	Evaluation of placental growth factor and soluble Fmsâ€like tyrosine kinase 1 as predictors of allâ€cause and cardiovascular mortality in patients with Type 1 diabetes with and without diabetic nephropathy. Diabetic Medicine, 2012, 29, 337-344.	2.3	14
184	Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes. Diabetic Medicine, 2015, 32, 1104-1109.	2.3	14
185	Comparing effects of insulin analogues and human insulin on nocturnal glycaemia in hypoglycaemiaâ€prone people with Type 1 diabetes. Diabetic Medicine, 2017, 34, 625-631.	2.3	14
186	Hypoglycemia-Associated EEG Changes Following Antecedent Hypoglycemia in Type 1 Diabetes Mellitus. Diabetes Technology and Therapeutics, 2017, 19, 85-90.	4.4	14
187	A polymorphism in the angiotensin II type 1 receptor gene has different effects on the risk of diabetic nephropathy in men and women. Molecular Genetics and Metabolism, 2011, 103, 66-70.	1.1	13
188	Vitamin D, carotid intimaâ€“media thickness and bone structure in patients with type 2 diabetes. Endocrine Connections, 2015, 4, 128-135.	1.9	13
189	Readmission to hospital of medical patients â€“ A cohort study. European Journal of Internal Medicine, 2017, 46, 19-24.	2.2	13
190	Pregnancy-associated plasma proteinÂA in a large cohort of TypeÂ1 diabetic patients with and without diabetic nephropathyâ€”a prospective follow-up study. Diabetic Medicine, 2007, 24, 1381-1385.	2.3	12
191	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study. BMJ Open, 2015, 5, e007791-e007791.	1.9	12
192	Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes. PLoS ONE, 2011, 6, e24053.	2.5	12
193	Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus. BMC Medical Genomics, 2009, 2, 41.	1.5	11
194	Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension. Journal of Human Hypertension, 2015, 29, 28-32.	2.2	11
195	Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial. BMJ Open, 2016, 6, e008377.	1.9	11
196	Prediction of excessive weight gain in insulin treated patients with type 2 diabetes. Journal of Diabetes, 2017, 9, 325-331.	1.8	11
197	Are Changes in Heart Rate Variability During Hypoglycemia Confounded by the Presence of Cardiovascular Autonomic Neuropathy in Patients with Diabetes?. Diabetes Technology and Therapeutics, 2017, 19, 91-95.	4.4	11
198	Continuous glucose monitoring adds information beyond HbA1c in well-controlled diabetes patients with early cardiovascular autonomic neuropathy. Journal of Diabetes and Its Complications, 2017, 31, 1389-1393.	2.3	11

#	Article	IF	Citations
199	Metformin may adversely affect orthostatic blood pressure recovery in patients with type 2 diabetes: substudy from the placebo-controlled Copenhagen Insulin and Metformin Therapy (CIMT) trial. Cardiovascular Diabetology, 2020, 19, 150.	6.8	11
200	The Xylosyltransferase I Gene Polymorphism c.343G>T (p.A125S) Is a Risk Factor for Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2006, 29, 2295-2299.	8.6	10
201	An IGF-I gene polymorphism modifies the risk of developing persistent microalbuminuria in type 1 diabetes. European Journal of Endocrinology, 2007, 156, 83-90.	3.7	10
202	The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design. BMC Endocrine Disorders, 2019, 19, 78.	2.2	10
203	Heart rate increases in liraglutide treated chronic heart failure patients: association with clinical parameters and adverse events. Scandinavian Cardiovascular Journal, 2020, 54, 294-299.	1.2	10
204	Genetic Variation of a Collagen IV Î±1-Chain Gene Polymorphism in Danish Insulin-dependent Diabetes Mellitus (IDDM) Patients: Lack of Association to Nephropathy and Proliferative Retinopathy. , 1997, 14, 143-147.		9
205	Infrared thermographic assessment of changes in skin temperature during hypoglycaemia in patients with type 1 diabetes. Diabetologia, 2015, 58, 1898-1906.	6.3	9
206	Effect of 12â€week continuous positive airway pressure therapy on glucose levels assessed by continuous glucose monitoring in people with type 2 diabetes and obstructive sleep apnoea; a randomized controlled trial. Endocrinology, Diabetes and Metabolism, 2021, 4, e00148.	2.4	9
207	Short-term oral treatment with the angiotensin II receptor antagonist losartan does not improve coronary vasomotor function in asymptomatic type 2 diabetes patients. Diabetes Research and Clinical Practice, 2009, 84, 34-38.	2.8	8
208	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. Nephron Clinical Practice, 2011, 118, c309-c314.	2.3	8
209	CD2AP is associated with end-stage renal disease in patients with type 1 diabetes. Acta Diabetologica, 2013, 50, 887-897.	2.5	8
210	The Degree of Autonomic Modulation Is Associated With the Severity of Microvascular Complications in Patients With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 681-686.	2.2	8
211	Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporosis International, 2021, 32, 1837-1848.	3.1	8
212	Aldosterone synthase (CYP11B2) -344T/C polymorphism is not associated with the initiation and progression of diabetic nephropathy in Caucasian Type 1 diabetic patients. Diabetic Medicine, 2006, 23, 675-680.	2.3	7
213	The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes. Journal of Negative Results in BioMedicine, 2011, 10, 4.	1.4	7
214	Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. Calcified Tissue International, 2020, 107, 160-169.	3.1	7
215	Effect of 12Âweeks continuous positive airway pressure on day and night arterial stiffness and blood pressure in patients with type 2 diabetes and obstructive sleep apnea: A randomized controlled trial. Journal of Sleep Research, 2020, 29, e12978.	3.2	7
216	Visitâ€toâ€visit variability of clinical risk markers in relation to longâ€term complications in type 1 diabetes. Diabetic Medicine, 2021, 38, e14459.	2.3	7

#	Article	IF	Citations
217	Aldosterone synthase (CYP11B2)Â344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Scandinavian Journal of Clinical and Laboratory Investigation, 2006, 66, 173-180.	1.2	6
218	Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1036-1045.	1.7	6
219	High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes. Journal of Diabetes and Its Complications, 2016, 30, 1603-1608.	2.3	6
220	Short-term cost-effectiveness of insulin detemir and insulin aspart in people with type 1 diabetes who are prone to recurrent severe hypoglycemia. Current Medical Research and Opinion, 2016, 32, 1719-1725.	1.9	6
221	Incident microalbuminuria and complement factor mannanâ€binding lectinâ€associated protein 19 in people with newly diagnosed type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2895.	4.0	6
222	Arterial stiffness in people with Type 2 diabetes and obstructive sleep apnoea. Diabetic Medicine, 2018, 35, 1391-1398.	2.3	6
223	Comparison of treatment with insulin degludec and glargine <scp>U100</scp> in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The <scp>HypoDeg</scp> randomized, controlled, openâ€label, crossover trial. Diabetes, Obesity and Metabolism, 2022, 24, 257-267.	4.4	6
224	Continuous Glucose Monitoring-Recorded Hypoglycemia with Insulin Degludec or Insulin Glargine U100 in People with Type 1 Diabetes Prone to Nocturnal Severe Hypoglycemia. Diabetes Technology and Therapeutics, 2022, 24, 643-654.	4.4	6
225	Preventing diabetic nephropathy: an audit. Scandinavian Journal of Clinical and Laboratory Investigation, 2001, 61, 471-477.	1.2	5
226	Relation of Left Ventricular Function, Mass, and Volume to NT-proBNP in Type 1 Diabetic Patients. Diabetes Care, 2008, 31, 968-970.	8.6	5
227	Paper Electrocardiograph Strips May Contain Overlooked Clinical Information in Screen-Detected Type 2 Diabetes Patients. Journal of Diabetes Science and Technology, 2012, 6, 74-80.	2.2	5
228	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 2019, 10, 242.	3.5	5
229	Comment on: Wanic et al. (2008) Exclusion of Polymorphisms in Carnosinase Genes (CNDP1 and) Tj ETQq1 1 0.784314 rgBT / Follow-Up Studies: Diabetes 57:2547â€“2551, 2008. Diabetes, 2008, 57, e16-e16.	0.6	4
230	Experimental testing of skin reactions to insulin detemir in diabetes patients naÃ¯ve to insulin detemir. Skin Research and Technology, 2011, 17, 411-419.	1.6	4
231	Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes. Diabetes Care, 2017, 40, e32-e33.	8.6	4
232	The potential for improvement of outcomes by personalized insulin treatment of type 1 diabetes as assessed by analysis of single-patient data from a randomized controlled cross-over insulin trial. Diabetes Research and Clinical Practice, 2017, 123, 143-148.	2.8	4
233	Reduced Inspiratory Muscle Strength in Patients with Type 2 Diabetes Mellitus and Obstructive Sleep Apnoea. Journal of Diabetes Research, 2017, 2017, 1-6.	2.3	4
234	ACE genotype, phenotype and all-cause mortality in different cohorts of patients with type 1 diabetes. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 374-381.	1.7	3

#	Article	IF	Citations
235	Validation of an Algorithm for Predicting Hypoglycemia From Continuous Glucose Measurements and Heart Rate Variability Data. Journal of Diabetes Science and Technology, 2019, 13, 1178-1179.	2.2	3
236	Association between severe diabetic retinopathy and lectin pathway proteins â€“ an 18-year follow-up study with newly diagnosed type 1 diabetes patients. Immunobiology, 2020, 225, 151939.	1.9	3
237	Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European Journal of Endocrinology, 2008, 158, 443-445.	3.7	2
238	Review of Genetic Association in the SOD2 Gene with Chronic Kidney Disease: Case-Control Studies and Meta-Analysis Confirm Association with Diabetic Nephropathy. Nephrology Research & Reviews, 2012, 4, 51-54.	0.2	2
239	Effect of Continuous Glucose Monitoring Accuracy on Cliniciansâ€™ Retrospective Decision Making in Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1092-1102.	2.2	2
240	<scp>ACTH</scp> stimulation test in patients with type 1 diabetes and recurrent severe hypoglycaemia. Clinical Endocrinology, 2015, 82, 155-156.	2.4	1
241	Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107681.	2.3	1
242	Improving Diabetes Self-management by Providing Continuous Positive Airway Pressure Treatment to Patients With Obstructive Sleep Apnea and Type 2 Diabetes: Qualitative Exploratory Interview Study. JMIR Formative Research, 2021, 5, e27062.	1.4	1
243	Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine, 2022, 178, 18-25.	2.9	1